Submission of Matters to a Vote of Security Holders
→
1/10/25
Agreement
Entry into a Material Definitive Agreement
→
12/30/24
Reg FD
Regulation FD Disclosure
→
↓
Prospectuses & Registrations
25 shown
Filed
Form
Description
3/3/26
S-8
S-8
→
3/3/26
S-3ASR
S-3ASR
→
9/10/25
424B5
424B5
→
9/9/25
424B5
424B5
→
4/24/25
ARS
ARS
→
3/4/25
S-8
S-8
→
↓
Filing History(395 filings)
TypeDateAccessionPeriodSize
4
Mar 9, 2026
0001193125-26-0984404
Mar 5, 2026
7.0 KB
4
Mar 9, 2026
0001193125-26-0984394
Mar 5, 2026
7.1 KB
4
Mar 9, 2026
0001193125-26-0984384
Mar 5, 2026
10.5 KB
4
Mar 9, 2026
0001193125-26-0984374
Mar 5, 2026
7.1 KB
4
Mar 9, 2026
0001193125-26-0984364
Mar 5, 2026
7.1 KB
4
Mar 4, 2026
0001193125-26-0914434
Mar 2, 2026
5.1 KB
4
Mar 4, 2026
0001193125-26-0914424
Mar 2, 2026
5.1 KB
4
Mar 4, 2026
0001193125-26-0914404
Mar 2, 2026
5.1 KB
4
Mar 4, 2026
0001193125-26-0914384
Mar 2, 2026
8.5 KB
4
Mar 4, 2026
0001193125-26-0914364
Mar 2, 2026
5.1 KB
S-8
Mar 3, 2026
0001193125-26-088117S-8
—
167.3 KB
S-3ASR
Mar 3, 2026
0001193125-26-086735S-3ASR
—
1.0 MB
10-K
Mar 3, 2026
0001193125-26-08664510-K
Dec 31, 2025
12.8 MB
8-K
Mar 3, 2026
0001193125-26-0866298-K
Mar 3, 2026
390.4 KB
144
Mar 2, 2026
0001898314-26-000002
—
7.1 KB
144
Mar 2, 2026
0001326969-26-000002
—
5.1 KB
144
Mar 2, 2026
0001235598-26-000002
—
5.7 KB
144
Mar 2, 2026
0001913765-26-000002
—
5.8 KB
144
Mar 2, 2026
0001898644-26-000002
—
7.1 KB
4
Feb 25, 2026
0001193125-26-0714604
Feb 23, 2026
5.1 KB
144
Feb 23, 2026
0001193125-26-064078
—
5.1 KB
SCHEDULE 13G/A
Feb 17, 2026
0001193125-26-054741
—
13.1 KB
SCHEDULE 13G/A
Feb 12, 2026
0000902664-26-000907
—
12.2 KB
SCHEDULE 13G/A
Feb 5, 2026
0000315066-26-000374
—
11.3 KB
4
Feb 4, 2026
0001193125-26-0375534
Feb 2, 2026
8.5 KB
25 filings shown
Amylyx Pharmaceuticals, Inc. — SlamSEC
Proxies
8 shown
Filed
Form
Description
4/24/25
DEFA14A
DEFA14A
→
4/24/25
DEF 14A
DEF 14A
→
4/24/24
DEFA14A
DEFA14A
→
4/24/24
DEF 14A
DEF 14A
→
4/27/23
DEFA14A
DEFA14A
→
4/27/23
DEF 14A
DEF 14A
→
↓
Ownership
40 shown
Filed
Form
Description
3/9/26
4
4
→
3/9/26
4
4
→
3/9/26
4
4
→
3/9/26
4
4
→
3/9/26
4
4
→
3/4/26
4
4
→
↓
Other Filings
40 shown
Filed
Form
Description
3/2/26
144
144
→
3/2/26
144
144
→
3/2/26
144
144
→
3/2/26
144
144
→
3/2/26
144
144
→
2/23/26
144
144
→
↓
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis.